{"id":74281,"date":"2026-04-20T18:12:29","date_gmt":"2026-04-20T12:42:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=74281"},"modified":"2026-04-20T18:12:31","modified_gmt":"2026-04-20T12:42:31","slug":"vivimed-labs-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/","title":{"rendered":"Vivimed Labs Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"},"content":{"rendered":"<p>Vivimed Labs (NSE: VIVIMED) is preparing to announce its Q4 FY26 (January\u2013March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 85 \u2014 against a 52-week high of Rs 125 and a 1-year return of -22% \u2014 the Q4 FY26 results will be a pivotal event for investors monitoring the API \/ Specialty Pharma \/ Personal Care sector.<\/p><p>Analyst consensus estimates for Q4 FY26 stand at Rs 420\u2013480 Cr in revenue and Rs 12\u201318 Cr in profit after tax, with margin expectations of EBITDA 8\u201310%. The key growth metric of Revenue +8\u201312% YoY will be watched alongside FY27 management guidance \u2014 which analysts consider the most important output from the Q4 FY26 announcement.<\/p><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Univest<\/strong><\/a>.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Vivimed_Labs_Q4_Results_2026_Date\" title=\"Vivimed Labs Q4 Results 2026 Date\">Vivimed Labs Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Vivimed_Labs_Q4_FY26_Earnings_Estimates\" title=\"Vivimed Labs Q4 FY26 Earnings Estimates\">Vivimed Labs Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Vivimed_Labs_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Vivimed Labs Q4 FY26 Performance\">5 Key Factors That Will Drive Vivimed Labs Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#1_API_Specialty_Pharma_Personal_Care_Sector_Demand_Momentum\" title=\"1. API \/ Specialty Pharma \/ Personal Care Sector Demand Momentum\">1. API \/ Specialty Pharma \/ Personal Care Sector Demand Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#2_Revenue_Growth_of_Revenue_8%E2%80%9312_YoY\" title=\"2. Revenue Growth of Revenue +8\u201312% YoY\">2. Revenue Growth of Revenue +8\u201312% YoY<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#3_Margin_Delivery_at_EBITDA_8%E2%80%9310\" title=\"3. Margin Delivery at EBITDA 8\u201310%\">3. Margin Delivery at EBITDA 8\u201310%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#4_FY27_Guidance_%E2%80%94_The_Single_Most_Critical_Catalyst\" title=\"4. FY27 Guidance \u2014 The Single Most Critical Catalyst\">4. FY27 Guidance \u2014 The Single Most Critical Catalyst<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#5_Dividend_or_Capital_Allocation_Signal\" title=\"5. Dividend or Capital Allocation Signal\">5. Dividend or Capital Allocation Signal<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#5_Risks_to_Watch_in_Vivimed_Labs_Q4_FY26\" title=\"5 Risks to Watch in Vivimed Labs Q4 FY26\">5 Risks to Watch in Vivimed Labs Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#1_US_Tariff_Macro_Headwinds\" title=\"1. US Tariff Macro Headwinds\">1. US Tariff Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#2_Results_Miss_Versus_Estimates\" title=\"2. Results Miss Versus Estimates\">2. Results Miss Versus Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#3_FY27_Guidance_Disappointment\" title=\"3. FY27 Guidance Disappointment\">3. FY27 Guidance Disappointment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#4_Competitive_Pressure_in_API_Specialty_Pharma_Personal_Care\" title=\"4. Competitive Pressure in API \/ Specialty Pharma \/ Personal Care\">4. Competitive Pressure in API \/ Specialty Pharma \/ Personal Care<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#5_FII_Selling_and_Liquidity_Risk\" title=\"5. FII Selling and Liquidity Risk\">5. FII Selling and Liquidity Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Vivimed_Labs_Share_Price_and_Analyst_Ratings\" title=\"Vivimed Labs Share Price and Analyst Ratings\">Vivimed Labs Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_What_is_the_Vivimed_Labs_Q4_results_2026_date\" title=\"Q: What is the Vivimed Labs Q4 results 2026 date?\">Q: What is the Vivimed Labs Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_What_is_the_Vivimed_Labs_Q4_FY26_PAT_estimate\" title=\"Q: What is the Vivimed Labs Q4 FY26 PAT estimate?\">Q: What is the Vivimed Labs Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_What_is_Vivimed_Labss_share_price_ahead_of_Q4_results\" title=\"Q: What is Vivimed Labs&#8217;s share price ahead of Q4 results?\">Q: What is Vivimed Labs&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_Will_Vivimed_Labs_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Vivimed Labs declare a dividend in Q4 FY26?\">Q: Will Vivimed Labs declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_Which_analysts_have_a_Buy_rating_on_Vivimed_Labs\" title=\"Q: Which analysts have a Buy rating on Vivimed Labs?\">Q: Which analysts have a Buy rating on Vivimed Labs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_What_were_Vivimed_Labs_Q3_FY26_results\" title=\"Q: What were Vivimed Labs Q3 FY26 results?\">Q: What were Vivimed Labs Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"Q: When do Infosys and TCS announce Q4 results 2026?\">Q: When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Q_Is_Vivimed_Labs_a_good_investment_ahead_of_Q4_results\" title=\"Q: Is Vivimed Labs a good investment ahead of Q4 results?\">Q: Is Vivimed Labs a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/vivimed-labs-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vivimed_Labs_Q4_Results_2026_Date\"><\/span><strong>Vivimed Labs Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>The Vivimed Labs Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter and full year ended March 31, 2026.<\/p><p>Here is the broader Q4 FY26 earnings calendar for major Indian companies:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Key Watch<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>Apr 9, 2026 <\/td><td>PAT Rs 13,718Cr; dividend Rs 31\/share<\/td><\/tr><tr><td>Wipro<\/td><td>Apr 16, 2026 <\/td><td>PAT Rs 3,502Cr; buyback Rs 15,000Cr<\/td><\/tr><tr><td>Waaree Renewable<\/td><td>Apr 16, 2026 <\/td><td>Solar EPC Q4 results declared<\/td><\/tr><tr><td>HDFC Bank<\/td><td>Apr 18, 2026 <\/td><td>NIM recovery; Q4 PAT watch<\/td><\/tr><tr><td>Yes Bank<\/td><td>Apr 18, 2026<\/td><td>NIM 2.5\u20132.7%; NPA cleanup progress<\/td><\/tr><tr><td>Infosys<\/td><td>Apr 23, 2026<\/td><td>FY27 CC revenue guidance \u2014 critical<\/td><\/tr><tr><td>IndusInd Bank<\/td><td>Apr 24, 2026<\/td><td>Derivative restatement resolution<\/td><\/tr><tr><td>Coal India<\/td><td>Apr 27, 2026<\/td><td>Volume decline + dividend<\/td><\/tr><\/tbody><\/table><\/figure><p>For the complete Q4 FY26 results calendar and real-time announcements, visit <a href=\"https:\/\/univest.in\/blogs\"><strong>Univest Blogs<\/strong><\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Q4 FY26 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Vivimed Labs, with a stock return of -22% over the past year, this quarter&#8217;s results and FY27 guidance are critical for determining whether the stock can recover or faces continued pressure.<\/p><p>Beyond the headline revenue of Rs 420\u2013480 Cr and PAT of Rs 12\u201318 Cr, investors will focus on three areas: (1) whether FY27 guidance meets consensus expectations for Revenue +8\u201312% YoY, (2) whether the EBITDA 8\u201310% margin is sustainable or under pressure, and (3) the dividend or buyback announcement of Nil. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vivimed_Labs_Q4_FY26_Earnings_Estimates\"><\/span><strong>Vivimed Labs Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196.jpeg\" alt=\"Vivimed Labs Q4 FY26 Analyst Estimates\" class=\"wp-image-74283\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Univest<\/strong><\/a>.<\/p><p>Brokerages including MOFSL, YES Securities, and JM Financial project Rs 420\u2013480 Cr in revenue (Q3 actual: Rs 388 Cr) and PAT of Rs 12\u201318 Cr (Q3 actual: Rs 13 Cr). A beat on revenue combined with margin expansion or positive FY27 guidance would be the most positive scenario for the stock.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Key Watch<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 388 Cr<\/td><td>Rs 420\u2013480 Cr<\/td><td>Sequential trajectory<\/td><\/tr><tr><td>PAT<\/td><td>Rs 13 Cr<\/td><td>Rs 12\u201318 Cr<\/td><td>Clean earnings quality<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 8.5%<\/td><td>EBITDA 8\u201310%<\/td><td>Pricing and cost control<\/td><\/tr><tr><td>Growth Metric<\/td><td>Q3 base<\/td><td>Revenue +8\u201312% YoY<\/td><td>Volume \/ Rate \/ SSG<\/td><\/tr><tr><td>Dividend<\/td><td>\u2014<\/td><td>Nil<\/td><td>FCF signal<\/td><\/tr><\/tbody><\/table><\/figure><p>Screen <a href=\"https:\/\/univest.in\/screeners\"><strong>Vivimed Labs<\/strong><\/a> live fundamentals, FII\/DII activity, and analyst upgrades on the Univest Screener.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Vivimed_Labs_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Vivimed Labs Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_API_Specialty_Pharma_Personal_Care_Sector_Demand_Momentum\"><\/span><strong>1. API \/ Specialty Pharma \/ Personal Care Sector Demand Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Vivimed Labs operates in the API \/ Specialty Pharma \/ Personal Care sector \u2014 one of India&#8217;s structurally growing spaces with Q4 FY26 seasonal demand tailwinds. Q4 is typically the strongest quarter for most sectors due to year-end government capex acceleration, housing completions, and consumer spending peaks. Analyst consensus projects Rs 420\u2013480 Cr for Q4 FY26 \u2014 versus Rs 388 Cr in Q3 \u2014 implying strong execution execution is required. Track live fundamentals on&nbsp; <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Revenue_Growth_of_Revenue_8%E2%80%9312_YoY\"><\/span><strong>2. Revenue Growth of Revenue +8\u201312% YoY<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The key volume or rate metric of Revenue +8\u201312% YoY is the single most important operating variable analysts are tracking for Vivimed Labs&#8217;s Q4 FY26. A strong performance on this metric validates the structural investment thesis and is expected to drive positive stock price movement on results day. A miss versus consensus would likely trigger downward FY27 estimate revisions.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Margin_Delivery_at_EBITDA_8%E2%80%9310\"><\/span><strong>3. Margin Delivery at EBITDA 8\u201310%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations of EBITDA 8\u201310% (versus Q3 actual of EBITDA 8.5%) reflect the interplay of pricing power, input cost management, and operating leverage. If Vivimed Labs can sustain or expand margins while delivering estimated revenue, it would mark a continuation of the profitability improvement story and be positively received by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_FY27_Guidance_%E2%80%94_The_Single_Most_Critical_Catalyst\"><\/span><strong>4. FY27 Guidance \u2014 The Single Most Critical Catalyst<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The single most consequential output from the Q4 FY26 board meeting will be management&#8217;s FY27 guidance \u2014 revenue growth bands, margin targets, capex plans, and macro risk commentary. In the current global environment \u2014 shaped by US-India tariff negotiations and FII outflows \u2014 credible and specific FY27 guidance from Vivimed Labs will be valued more than the reported Q4 number. Monitor guidance announcements in real time on Univest.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Dividend_or_Capital_Allocation_Signal\"><\/span><strong>5. Dividend or Capital Allocation Signal<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Vivimed Labs is expected to consider Nil at the Q4 FY26 board meeting. The dividend quantum signals management&#8217;s confidence in free cash flow generation. For investors, dividend per share relative to the current market price of Rs 85 determines yield proposition and is a factor in institutional portfolio sizing decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Vivimed_Labs_Q4_FY26\"><\/span><strong>5 Risks to Watch in Vivimed Labs Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_US_Tariff_Macro_Headwinds\"><\/span><strong>1. US Tariff Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods \u2014 announced April 2, 2026 \u2014 has created FII outflow pressure across Indian equities. For Vivimed Labs, indirect impacts include compresed earnings multiples and institutional de-allocation, even if the company&#8217;s own supply chain is not directly affected by the tariff.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Results_Miss_Versus_Estimates\"><\/span><strong>2. Results Miss Versus Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Vivimed Labs&#8217;s Q4 FY26 results miss analyst estimates of Rs 420\u2013480 Cr in revenue and Rs 12\u201318 Cr in PAT, the stock could correct sharply. The percentage correction is typically larger than the percentage miss \u2014 particularly for stocks that have underperformed in the prior 12 months.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_FY27_Guidance_Disappointment\"><\/span><strong>3. FY27 Guidance Disappointment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If management&#8217;s FY27 guidance falls below Street expectations \u2014 even with an in-line Q4 print \u2014 the stock may decline on forward estimate cuts. Management credibility is a function of historical guidance delivery; any slippage from prior guidance creates a double discount on new projections.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Competitive_Pressure_in_API_Specialty_Pharma_Personal_Care\"><\/span><strong>4. Competitive Pressure in API \/ Specialty Pharma \/ Personal Care<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The API \/ Specialty Pharma \/ Personal Care sector faces intensifying competition from domestic capacity additions and international entrants. Vivimed Labs&#8217;s ability to maintain pricing power, market share, and customer relationships in this environment is a structural risk factor for FY27 estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_FII_Selling_and_Liquidity_Risk\"><\/span><strong>5. FII Selling and Liquidity Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Global risk-off events can trigger concentrated institutional selling that disconnects stock price from underlying fundamentals. Mid- and small-cap stocks like Vivimed Labs are particularly vulnerable to liquidity-driven corrections on results day independent of the reported numbers.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vivimed_Labs_Share_Price_and_Analyst_Ratings\"><\/span><strong>Vivimed Labs Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Vivimed Labs is trading at Rs 85 as of April 2026, against a 52-week high of Rs 125 and a 52-week low of Rs 62. The 1-year return of -22% reflects the macro headwinds of FY26. Analyst 12-month targets range from Rs 110 to Rs 105, implying potential recovery from current levels contingent on Q4 execution and FY27 guidance delivery.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>12M Target<\/strong><\/td><td><strong>Investment Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Neutral<\/td><td>Rs 105<\/td><td>API + personal care dual<\/td><\/tr><tr><td>JM Financial<\/td><td>Neutral<\/td><td>Rs 98<\/td><td>Restructuring progress key<\/td><\/tr><tr><td>YES Securities<\/td><td>Neutral<\/td><td>Rs 110<\/td><td>Revenue normalisation underway<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> to track Vivimed Labs live price, charts, and receive real-time Q4 result alerts from SEBI-registered analysts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Vivimed Labs Q4 FY26 results on May 2026 (Expected) will be a key earnings event for investors monitoring the API \/ Specialty Pharma \/ Personal Care sector. With analyst consensus projecting revenue of Rs 420\u2013480 Cr and PAT of Rs 12\u201318 Cr, the stock at Rs 85 offers a risk-reward profile that depends on execution and FY27 guidance credibility. For more Q4 FY26 previews across sectors, visit <a href=\"https:\/\/univest.in\/blogs\"><strong>Univest Blogs<\/strong><\/a>.<\/p><p>Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions. For more Q4 FY26 results previews, visit Univest Blogs.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_the_Vivimed_Labs_Q4_results_2026_date\"><\/span>Q: What is the Vivimed Labs Q4 results 2026 date?<span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Vivimed Labs Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve audited Q4 FY26 financial results and consider a final dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_the_Vivimed_Labs_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is the Vivimed Labs Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Vivimed Labs Q4 FY26 PAT in the range of Rs 12\u201318 Cr, based on revenue of Rs 420\u2013480 Cr and margin of EBITDA 8\u201310%. Q3 FY26 actual PAT was Rs 13 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_is_Vivimed_Labss_share_price_ahead_of_Q4_results\"><\/span><strong>Q: What is Vivimed Labs&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Vivimed Labs is trading at Rs 85 as of April 2026. The 52-week high is Rs 125 and the 52-week low is Rs 62. The 1-year return is -22% and market capitalisation is Rs 520 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Will_Vivimed_Labs_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Vivimed Labs declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Vivimed Labs is expected to consider Nil at the Q4 FY26 board meeting. The quantum will be confirmed on the results announcement date.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Which_analysts_have_a_Buy_rating_on_Vivimed_Labs\"><\/span><strong>Q: Which analysts have a Buy rating on Vivimed Labs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>See full analyst ratings table above hold Buy ratings. Consult a SEBI-registered financial advisor before investing.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_What_were_Vivimed_Labs_Q3_FY26_results\"><\/span><strong>Q: What were Vivimed Labs Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Vivimed Labs reported Q3 FY26 (October\u2013December 2025) revenue of Rs 388 Cr and PAT of Rs 13 Cr, with margin at EBITDA 8.5%. Q3 actuals form the sequential base against which Q4 FY26 estimates are benchmarked.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>Q: When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026 \u2014 PAT Rs 13,718 crore and revenue Rs 70,698 crore, with a Rs 31\/share final dividend. Full preview at https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview. Infosys Q4 FY26 results are scheduled for April 23, 2026 \u2014 FY27 CC revenue guidance is the critical watch. Full preview at https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Q_Is_Vivimed_Labs_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Q: Is Vivimed Labs a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite, investment horizon, and portfolio context. Vivimed Labs has compelling factors \u2014 API + personal care dual \u2014 alongside genuine near-term risks including US tariff macro headwinds and FY27 guidance uncertainty. Analyst consensus targets range from Rs 110 to Rs 105. Consult a SEBI-registered financial advisor before investing.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/natural-capsules-q4-results-2026\">Natural Capsules Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-fertilizers-q4-results-2026\">National Fertilizers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/national-aluminium-company-q4-results-2026\">National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/nath-bio-genes-india-q4-results-2026\">Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/narmada-agrobase-q4-results-2026\">Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Vivimed Labs (NSE: VIVIMED) is preparing to announce its Q4 FY26 (January\u2013March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 85 \u2014 against a 52-week high of Rs 125 and a 1-year return of -22% \u2014 the Q4 FY26 results will be a pivotal event for investors<\/p>\n","protected":false},"author":28,"featured_media":74284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-74281","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"_edit_lock":["1776689145:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:2:{s:63:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-1196.jpeg\";a:2:{s:2:\"id\";i:74283;s:11:\"source_type\";s:13:\"media-library\";}s:95:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20180755\/image-1196.jpeg\";a:2:{s:2:\"id\";i:74283;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_description":["Vivimed Labs Q4 results on May 2026 (Expected). Revenue estimate Rs 420\u2013480 Cr, PAT estimate Rs 12\u201318 Cr. Analyst targets, key factors &amp; FY27 guidance watch."],"rank_math_title":["Vivimed Labs Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Vivimed Labs Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["74284"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["8570"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/20181016\/Vivimed-Labs-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=74281"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74281\/revisions"}],"predecessor-version":[{"id":74285,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/74281\/revisions\/74285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/74284"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=74281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=74281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=74281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}